Pharmaceuticals, biotechnology and medicine work togetherNearmedic for a healthy nation

Release of the monoclonal FITC labeled antibody preparation against LPS genus specific antigen of Chlamidia for the direct immunofluorescence test

Set up of the Nearmedic Plus training center

Development of the ChlaMonoScreen test kit for diagnosing сhlamidiosis

Development and start of production of IFA- and FAT- based kits for diagnosing toxoplasmosis, cytomegalovirus, pneumocystosis, herpes simplex virus, syphilis, various types of mycoplasmosis, ureaplasmosis, brucellosis

Development of test-systems for HBsAg of hepatitis B HepaStrip B virus

Start of joint project with Murex Biotech Company on registration and production of licensed 4th generation test-system for detection of antibodies to hepatitis C virus

Launch of production of LimphoScreen and MigroScreen kits for immune status estimation

Production of first diagnostic PCR based kits

Foundation of Nearmedic clinic and laboratory

Foundation of laboratory equipment department

Start up of pharmaceuticals development

Launch of new production line for GMP standards diagnostic test-systems

Production of proper test-systems for diagnosing syphilis and viral hepatitis C

Nearmedic cooperates with world leaders in diagnostics and lab equipment: Abbott Diagnostics (USA), Tecan (Switzerland), Europrobe (France) and others. Registration and start of local production of IFA kits HIV Ar/At Combotest under the license of Abbott/Murex Company and branded “Nearmedic plus”

Registration and launch of production of Kagocel antiviral agent

Launch of local production of confirming tests for antibodies to HIV (LIA HIV) and to hepatitis C virus (LIA VHC) under the Innogenetics Company (Belgium) license

Nearmed is awarded the status of lab equipment and HIV diagnostic kits official suppler within the “Health” National Project framework

Set up of company Pharmaceutical department aimed at Kagocel marketing development and increase of sales through the network of offices and medical representatives in 12 biggest cities and regions of Russia as well as in Ukraine

Registration of enlarged scale of indications for Kagocel use for influenza and ARVI treatment of children over 6 years. Kagocel is licensed in Republic of Belarus

Kagocel registration and start of sales in Ukraine

Deepening cooperation with blood institutions and AIDS fighting organizations. Installation of basic equipment in major part of Russia anti-AIDS Centers. Implementation of automated technologies in routine practice of infectious donor and non-donor screening

Kagocel is introduced into the List of vital and most important pharmaceuticals (LVMIP) and included in federal procurement regulatory system

Nearmedic clinics network expansion and set up of Nearmedic laboratory

Registration in Russia of highly sensitive 4th generation test “Determine HIV-1/2 Ag/AbCombo” for simultaneous detection of antigen and antibodies to HIV in serum, plasma and whole blood. Within 20 minutes it ensures HIV detection at most early stage

Start of local production and sales of RealTime HIV-1 tests for HIV load under Abbott Molecular license and “Nearmedic Plus” brand

Nearmedic supplied the first in Russia Flex-ID complex to FSSB Russian Center for forensic medical examination affiliated to the Ministry of Public Health and Social Development of Russian Federation

Nearmedic clinics network is awarded the Consumer Rights prize founded by Federal Service for control over consumer rights and human well-being

ROSNANO and Nearmedic signed agreement on founding a universal full cycle GMP-enterprise for original pharmaceuticals production. Beginning of “Nearmedic Farma” foundation

Nearmedic Company became laureate of Platinum Ounce 2011, the 12th Russian national open contest for pharmaceutics experts, having won the “Drug of the Year” nomination and the prize in “Vector of the Year” nomination

Kagocel antiviral agent won the “Platinum Ounce 2012” prize in sub nomination ‘Non-prescription agent” of “Drug of the Year” nomination

Nearmedic company, with support of Kaluga region Ministry of Public Health and together with SP “Kaluga Pharmaceutical Cluster”, organized the first regional forum dedicated to early diagnostics of cervix cancer

ROSNANO company declared successful exit of capital of the Nearmedic Pharma company – a ROSNANO and Nearmedic joint project

Kagocel takes 1st place in sales (in volume terms) among agents of its segment as for results of year 2013 (DSM group data)

Nearmedic company and Kagocel agent again become laureates of the Platinum Ounce award in nominations “Dynamics of the Year” and “Drug of the Year”

Nearmedic company wins the exclusive right for production and introduction into markets of Russia and other EuroAsian Patent Organization countries of unique antituberculous remedy developed by Nearmedic together with Swiss Federal Polytechnic University (EPFL)

Nearmedic together with Kaluga region Ministry of Public Health, Russian Medical Academy of Postgraduate Education (RMAPE) and International Union for fighting sexually transmitted infections (USTI RU) give a start in Kaluga region to a unique socially oriented project for early diagnostics of cervix precursor of cancer

Nearmedic clinics network and Nearmedic laboratory become laureates of “Consumer Rights and Service Quality” awards in “Medical Service” and “Laboratory Service” nominations respectfully

As to SC Remedium and Russian Association of International Pharmaceuticals Producers rating, Nearmedic takes 6th position in top 10 of leading pharmaceutical enterprises in Russia

Kagocel wins the Russian Pharma Awards prize

Separator and “centrifuge-shaker” system for separating stromal-vascular fraction (SVF) out of adipose tissue as well as test systems for tuberculosis diagnostics after the PCR method in real time successfully passed expert examination and were approved at the Skolkovo Fund

Kagocel became the most popular antiviral agent against cold and influenza as for sales in volume terms within its sector (DSM group). Informational and analytical periodical “Pharmatzevticheski Vestnik” rates it number 1.

Nearmedic projects for: <br/> (1) setting up Russia's first ever full cycle production line for human genetic identification and filiations agents <br/> (2) development of medical products line for bone tissue regeneration, based on technologies of native non reconstructed collagen separation, were approved by the Industry Development Fund expert council for getting a loan

Drugstore industry experts within the Green Cross award contest voted Kagocel the best non- prescription agents in Russia in 2015

Russian Business Chanel rating includes Nearmedic in top 50 most quickly growing companies in Russia

Nearmedic and Swiss Federal Polytechnic University (EPFL) joint project for development of unique anti-tuberculosis pharmaceutical wins silver prize at Swiss-Russian innovations award named after A.V.Suvorov

Kagocel is again nominated laureate of Russian Pharma Awards

After Alforum company data, Nearmedic chain of clinics heads top 10 of favorite private medical institutions

Nearmedic company published report on unique post-registration research of Kagocel agent “Treatment of influenza in Routine Clinical Practice – FLU-EE” and it gets included into international register of clinical trials ClinicalTrials.gov

Information and analytical periodical “Pharmatzevticheski Vestnik” rates Kagocel antiviral agent number 1 in top 10 most influential non-prescription drugs

DSM Group recognizes Kagocel the leader of sales in terms of volume in 2016 among antiviral agents

Beginning of cooperation with Medinnovation Gmbh company

SC Nearmedic laboratory started production of the EPR test (Berlin) for diagnosing cancer at very early, including pre-clinical, stage

Kagocel is registered in National Clinical Protocol in the Republic of Moldova for anti-influenza and –ARVI treatment of children over 3 years

Launch of website on new medical products applied in regenerative medicine http://jointechcell.com/

Nearmedic Pharma production company joins the Union of industrialists and entrepreneurs of Kaluga region

Russia Dentists Association issued Quality Certificate to COLLOST collagen biomaterial

Kagocel brand launched a website myinformedchoice.rf where anyone can share his/her story of making the choice that changed his/her life

Kagocel wins the “Antimicrobial agents for systematic use” nomination of the Product of the Year 2017 award

Kagocel wins the Russian Pharma Awards 2017 again

COLLOST is included into clinical recommendations for treatment of decubital trophic ulcers

Matriflex line of products passed the 1st stage of preclinical trials

PBTZ 169 anti-tuberculosis agent passed the IIa phase of clinical trials (in 13 medical centers) – study of early bactericidal activity (EBA)

National Pharmaceutical Rating declared Kagocel #1 non-prescription agent in Russia in nomination “OTC drugs”

KAGOCEL in #20 packages was released in the market

KAGOCEL supported the Russian global musical flash mob When Your Girlfriend Falls Ill

KAGOCEL won the Green Cross award in the nomination Medication of Choice for the Prevention and Treatment of ARVI and Influenza

KAGOCEL became the winner of the Product of the Year award in the nomination Antimicrobials for Systemic Use

Matriflex (Nearmedic’s subsidiary company) received the Patent of Invention which will form the basis for the new line of medical products for the regeneration of bone tissue

The Nearmedic company launched Russia’s first ever full cycle production of reagents for genetic identification and establishment of kinship

A research titled Study of Collost 7% regenerative collagen complex efficiency and safety in the correction of age changes in facial skin was conducted using the facilities of the Institute for Plastic Surgery and Cosmetology and the Academician N.F. Izmerov Research Institute for Medicine of Labor

The name for the antituberculosis medicine PBTZ169 received official approval. The official name of the medicine approved by WHO is MAKOZINON

Clinical studies of the antituberculosis medicine PBTZ169 were completed

KAGOCEL won the Russian Pharma Awards in the nomination The Most Often Prescribed Drug in the Treatment of ARVI and Influenza

Full scale in-vivo study of the new line of medical products for the regeneration of bone tissue efficiency and safety was completed. The study was conducted in the framework of preclinical trial and further registration

Nearmedic’s full cycle production production of reagents for genetic identification and establishment of kinship was granted the ISO certificate #18385

KAGOCEL became the leader of the National Pharmaceutical Rating 2018 in the nomination Russian Brand in the Retail Market

KAGOCEL was granted the Choice of the Year title in Belarus

KAGOCEL has been recognized as No. 1 antiviral drug by the DSM Group

Niarmedic received a special prize «For innovative approach in the field of cross-media advertising»

KAGOCEL brand initiatives have been noted by the program «Best social projects in Russia»

The Matriflex company has developed and patented a unique method of purification, modification and sterilization of the derivatives of bone tissue and dermal matrix with the use of a supercritical fluid

KAGOCEL became No. 1 drug to treat SARS and influenza according to Smartpharma® Awards 2019

The Nearmediccompany received a certificate of quality control testing for the Gednap (Germany) DNA typing

A KAGOCEL project became the winner in two nominations of the Silver Mercury festival

A subsidiary of Nearmedic, Matriflex, has developed and patented a method for the production and application of a highly purified mineral matrix with osteoinductive properties designed for the repair of bone defects to be used in the production of the Bongraf APATITE medical product

KAGOCEL took the first place in the nomination «Antiviral agent No. 1 for adults and children from 3 years» at the Russian Pharma Awards 2019

The Nearmedic company received a registration certificate for the express system for detection of drugs and alcohol in human saliva

The chains of Nearmedic and Doctor Next Door clinics announced their intention to create a new company

The JoinTechCell company, part of the Nearmedic Group, received a patent for the method of casting the device for fractionation of adipose tissue

A Nearmedic publication on reagents has been published in the Forensic Science International: Genetics Supplement Series international journal

KAGOCEL was recognized as the best product in the category «Antiviral drug» in the framework of the annual national Consumer Confidence Award RUSSIA’S NO. 1 BRAND® 2019

COLLOST has been included in the international Spinal Cord Injury Recommendations

KAGOCEL became the 2019 No.1 Russian brand in the retail market according to the National Pharmaceutical Rating

The Nearmedic company received certificates of compliance with the EN ISO 13485 and EN ISO 9001requirements for its ESVIEF medical device production

The Nearmedic group and Sistema-Biotech launched contract production of Russian diagnostic kits for detecting coronavirus infection

Kagocel’s advertising campaigns won the Silver Mercury festival awards

In vitro studies showed high antiviral activity of KAGOCEL against COVID-19

KAGOCEL was recognized as No.1 antiviral agent by the Smartpharma Awards 2020

A study of the effectiveness of bone defect replacement with the use of Matriflex COLLAGEN showed that the medical product is comparable in effectiveness to the Geistlich Bio-Oss® bone substitute produced in Switzerland

JoinTechCell LLC, a member of the Nearmedic group, received the first international patent for the ESVIEF set for isolation of stromal-vascular fraction from adipose tissue to be used in regenerative medicine

The results of pre-registration tests of the effectiveness and safety of Matriflex products were published in an authoritative Swiss scientific journal Materials

Nearmedic Plus LLC started mass production of test systems developed by the N. F. Gamaleya National Research Center for the determination of protective immunity to the SARS-CoV-2 virus

The commercial Family Law created by the marketing team of the antiviral brand Kagocel, won at the MedMen Healthcare Creative Awards

Two studies of the drug Kagocel have been included in the international database of clinical trials ClinicalTrials.gov

The ESVIEF received a registration certificate

Kagocel wins Russian Pharma Awards

Kagocel wins the Choice of the Year contest in Belarus